ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2428

Epstein-Barr Virus Infection and Epstein-Barr Virus Nuclear Antigen 1 Variants in the Synovial Tissue of Rheumatoid Arthritis

Shotaro Masuoka1, Natsuko Kusunoki1, Shinichi Kawai2 and Toshihiro Nanki1, 1Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan, 2Department of Inflammation and Pain Control Research, Toho University School of Medicine, Tokyo, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Infection, Osteoarthritis, rheumatoid arthritis (RA) and viruses

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Epstein-Barr virus (EBV) infection causes various malignant tumors such as B cell lymphoma and epithelial cell cancer. Previous reports showed several variants in carboxyl-terminal region of EBV nuclear antigen 1 (EBNA-1), and the mutation was frequently detected in patients with nasopharyngeal carcinoma. The mutation of EBV gene may trigger development of the malignant cells. It was reported that titer of anti-EBV antibody was higher in rheumatoid arthritis (RA) compared to controls. Interestingly, the protein sequence of EBV gp110 glycoprotein resembles HLA DRB1 shared epitope (SE). These data suggest EBV infection may play a role of RA, however, underlying mechanisms remains unknown. Moreover, mutation of EBV in RA patients has not been examined. We then investigated EBNA-1 carboxy-terminal region in the synovial tissue of RA.

Methods: One hundred twenty-eight RA and 98 osteoarthritis (OA) patients undergoing joint surgery of the knee at the Toho University Omori Medical Center were enrolled in this study. Synovial tissues were collected during surgery under sterile condition. Informed consent was obtained from all the patients. DNA was extracted from the synovial tissues. The EBV gene was determined by nested PCR for amplifying EBNA-1 carboxy-terminal region, and then, the amplicons were detected by performing electrophoresis. Nucleotide sequence of the PCR product was determined. HLA DRB1 genotyping was also performed.

Results: EBV DNA was more frequently detected in synovial tissue from RA patients (32.8%; 42 of 128) than OA patient (15.3%; 15 of 98) (p<0.01, chi-squared test). The sequence of EBNA-1 carboxy-terminal revealed Japanese prototype (V-Val subtype) in 35 of the 42 RA (83.3%) and 13 of the 15 OA (86.7%) patients. Although four other subtypes were also detected in small number of patients, there were no significant differences between RA and OA. Frequency of HLA-DRB1*0405, *0410, *1001 (SE) was significantly higher in RA (55.5%) than OA (30.6%). Proportion of EBV-positive tended to be higher in SE-positive (39.4%; 28 of 71) than SE-negative (24.6%; 14 of 57), although it is not statistically significant.

Conclusion:

EBV infection might be an environmental risk factor for development or chronic synovitis of RA. However, nucleotide mutations of EBNA-1 may not contribute it.


Disclosure: S. Masuoka, None; N. Kusunoki, None; S. Kawai, None; T. Nanki, None.

To cite this abstract in AMA style:

Masuoka S, Kusunoki N, Kawai S, Nanki T. Epstein-Barr Virus Infection and Epstein-Barr Virus Nuclear Antigen 1 Variants in the Synovial Tissue of Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/epstein-barr-virus-infection-and-epstein-barr-virus%e3%80%80nuclear-antigen-1-variants-in-the-synovial-tissue-of-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/epstein-barr-virus-infection-and-epstein-barr-virus%e3%80%80nuclear-antigen-1-variants-in-the-synovial-tissue-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology